RECOGNIZE the complex pathophysiology of CKD, including the increased risks of cardiovascular and renal events and the roles of mineralocorticoid receptor and aldosterone in disease progression
RECOGNIZE the complex pathophysiology of CKD, including the increased risks of cardiovascular and renal events and the roles of mineralocorticoid receptor and aldosterone in disease progression Strongly agree
RECOGNIZE the complex pathophysiology of CKD, including the increased risks of cardiovascular and renal events and the roles of mineralocorticoid receptor and aldosterone in disease progression Agree
RECOGNIZE the complex pathophysiology of CKD, including the increased risks of cardiovascular and renal events and the roles of mineralocorticoid receptor and aldosterone in disease progression Neutral
RECOGNIZE the complex pathophysiology of CKD, including the increased risks of cardiovascular and renal events and the roles of mineralocorticoid receptor and aldosterone in disease progression Disagree
RECOGNIZE the complex pathophysiology of CKD, including the increased risks of cardiovascular and renal events and the roles of mineralocorticoid receptor and aldosterone in disease progression Strongly disagree
INTEGRATE evidence-based screening and diagnostic processes into the early recognition of CKD
INTEGRATE evidence-based screening and diagnostic processes into the early recognition of CKD Strongly agree
INTEGRATE evidence-based screening and diagnostic processes into the early recognition of CKD Agree
INTEGRATE evidence-based screening and diagnostic processes into the early recognition of CKD Neutral
INTEGRATE evidence-based screening and diagnostic processes into the early recognition of CKD Disagree
INTEGRATE evidence-based screening and diagnostic processes into the early recognition of CKD Strongly disagree
REVIEW recent clinical trial outcomes expanding on the use of mineralocorticoid receptor antagonists for patients with CKD
REVIEW recent clinical trial outcomes expanding on the use of mineralocorticoid receptor antagonists for patients with CKD Strongly agree
REVIEW recent clinical trial outcomes expanding on the use of mineralocorticoid receptor antagonists for patients with CKD Agree
REVIEW recent clinical trial outcomes expanding on the use of mineralocorticoid receptor antagonists for patients with CKD Neutral
REVIEW recent clinical trial outcomes expanding on the use of mineralocorticoid receptor antagonists for patients with CKD Disagree
REVIEW recent clinical trial outcomes expanding on the use of mineralocorticoid receptor antagonists for patients with CKD Strongly disagree